Analysts Set Teva Pharmaceutical Industries Limited (NYSE:TEVA) Target Price at $18.89

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) have earned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $18.89.

A number of brokerages have recently issued reports on TEVA. Jefferies Financial Group increased their price objective on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Barclays lifted their price target on shares of Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 3rd. UBS Group lifted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, May 30th.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the sale, the insider now owns 45,060 shares in the company, valued at approximately $777,285. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.55% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TEVA. Maple Rock Capital Partners Inc. grew its position in shares of Teva Pharmaceutical Industries by 68.3% during the 1st quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock worth $61,568,000 after buying an additional 1,770,000 shares during the period. Glenview Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $16,752,000. Iron Triangle Partners LP grew its position in shares of Teva Pharmaceutical Industries by 113.1% during the 1st quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock worth $39,083,000 after buying an additional 1,469,864 shares during the period. Driehaus Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $23,115,000. Finally, Norges Bank acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $14,376,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 1.8 %

Shares of TEVA stock opened at $18.07 on Tuesday. Teva Pharmaceutical Industries has a 52-week low of $8.06 and a 52-week high of $19.08. The stock has a market cap of $20.47 billion, a price-to-earnings ratio of -44.07, a P/E/G ratio of 1.26 and a beta of 0.88. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89. The firm has a fifty day moving average of $17.59 and a 200-day moving average of $15.99.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. The company had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $3.99 billion. On average, equities research analysts forecast that Teva Pharmaceutical Industries will post 2.33 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.